Announcement on behalf of OBIGEN that it has submitted the application of its two pivotal phase 3 studies for OBI-858 to TFDA

Date of occurrence of the event:2025/06/26 New drug name or code:OBI-858 Novel Botulinum Neurotoxin Indication: OBI-858, a self-developed novel botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic uses. Patents for its special molecular weight have been granted in US, Taiwan, Australia, New Zealand, Korea, Japan, Russia, Kingdom of Saudi Arabia, Indonesia, Malaysia, and […]